Orthogon Therapeutics Raises an Additional $11M Financing for Its BK Virus Antiviral Drug Program

Contributed by: Business Wire

Logo

Images

Electron microscope image of BK virus, showing the VP1 capsid protein that creates an icosahedral shell around the viral genome.

BK virus infected human kidney epithelial cell

Business Wire embedded0

Tags

Biotechnology

Health

Venture Capital

Finance

Other Health

Pharmaceutical

Surgery

Professional Services

Other Science

Research

Infectious Diseases

General Health

Hospitals

Science

Orthogon Therapeutics

More Like This

Ultrastructural representation of the BK polyomavirus capsid, featuring 72 pentamers that form its distinct icosahedral symmetry. (Graphic: Business Wire)

Orthogon Therapeutics Closes Oversubscribed $5.2M Financing to Advance First Oral Therapy for BK Polyomavirus

SpikImm Announces the Signature of an Exclusive License Option and Collaboration Agreement With SATT Conectus for the Development of a Prophylactic Treatment Against the BK Virus, Causing Severe Complications in Transplant Patients

Vertex Announces Key Advancements Across Kidney Portfolio

GlobeNewswire associated0

4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy

PR Newswire associated0

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

PR Newswire associated0

YGION Biomedical announces €15 Million Series A Financing to develop Individualized Cancer Immunotherapies